Fisetin for Inflammation and Allergy

Before fisetin became the senolytic flavonoid in 2018, it was already established in the natural-medicine literature as a quercetin-class anti-inflammatory and mast-cell-stabilizing flavonoid. The foundational work was Park et al. 2007 in Archives of Pharmacal Research, demonstrating that fisetin inhibits histamine release from mast cells and suppresses the expression of proinflammatory cytokines (IL-6, IL-8, TNF-α) through NF-κB inhibition. Hendriks et al. 2008 extended this work in immune-cell models and helped establish the mechanism. Subsequent studies have documented effects in allergic asthma models, atopic dermatitis pilot data, inflammatory bowel disease models, and rheumatoid arthritis models. Mechanistically the effects are nearly identical to quercetin — both flavonols inhibit NF-κB, stabilize mast cells against IgE-triggered degranulation, suppress COX-2 and pro-inflammatory cytokines, and reduce the inflammatory cytokine production of activated macrophages. Fisetin's practical advantage over quercetin is somewhat better membrane permeability, which translates to better cell-uptake and potentially better tissue penetration at comparable doses. This deep-dive walks through the older but clinically more-established anti-inflammatory and anti-allergic literature, where fisetin has a stronger evidence base than for its widely-marketed but newer senolytic application.

Table of Contents

  1. Fisetin as a Quercetin-Class Flavonol
  2. Park 2007 — Mast Cell Histamine Suppression
  3. Hendriks 2008 — NF-κB and Cytokine Suppression
  4. NF-κB Inhibition Mechanism
  5. Mast Cell Stabilization in Detail
  6. Allergic Asthma and Airway Inflammation
  7. Atopic Dermatitis and Skin Allergy
  8. Inflammatory Bowel Disease Models
  9. Rheumatoid and Osteoarthritis Applications
  10. COX-2 and Pro-Inflammatory Cytokine Suppression
  11. Practical Anti-Inflammatory Use Cases
  12. Key Research Papers
  13. Connections

Fisetin as a Quercetin-Class Flavonol

Quercetin is the most widely-used and best-studied flavonol in human nutritional supplementation, with dozens of clinical trials in asthma, allergic rhinitis, atopic dermatitis, cardiovascular outcomes, and exercise performance. The Park 2007 paper that first identified fisetin's anti-inflammatory activity explicitly framed fisetin as a quercetin-class compound — identical core flavonol structure with a single missing hydroxyl group on the B-ring, similar pharmacology, similar but somewhat distinct binding affinity profiles.

The structural similarity translates to mechanistic similarity. Both compounds:

The differences are quantitative rather than qualitative. Fisetin appears to have somewhat better membrane permeability owing to slightly higher lipophilicity (logP ~3.2 for fisetin vs ~1.5 for quercetin). This translates to better cell-uptake at comparable extracellular concentrations and potentially better tissue penetration, including across the blood-brain barrier. Fisetin also has somewhat longer plasma half-life in some preparations.

For practical purposes, fisetin and quercetin can be considered interchangeable for the basic anti-inflammatory and anti-allergic applications, with fisetin having a slight edge for applications requiring tissue penetration (CNS, skin) and quercetin having the larger published evidence base for outcomes like exercise-induced inflammation and allergic rhinitis. Many practitioners use both, either separately or in combination.

Back to Table of Contents

Park 2007 — Mast Cell Histamine Suppression

The seminal paper for fisetin in the anti-allergic / anti-inflammatory space is Park HH, Lee S, Son HY, Park SB, Kim MS, Choi EJ, Singh TSK, Ha JH, Lee MG, Kim JE, Hyun MC, Kwon TK, Kim YH, Kim SH. “Flavonoids inhibit histamine release and expression of proinflammatory cytokines in mast cells.” Archives of Pharmacal Research, 2007. Key findings:

The Park 2007 paper established the foundation for using fisetin in any IgE-mediated allergic condition (allergic rhinitis, atopic dermatitis, allergic asthma, urticaria, anaphylaxis) on the same mechanistic basis as quercetin. Most subsequent fisetin anti-allergic work has built on this foundation.

Back to Table of Contents

Hendriks 2008 — NF-κB and Cytokine Suppression

The Hendriks et al. 2008 work extended the Park findings into broader immune-cell models. Working with macrophages, T cells, and other immune-effector cells, Hendriks demonstrated that fisetin's NF-κB inhibition produces widespread suppression of pro-inflammatory cytokine production across multiple cell types, not just mast cells. This established fisetin as a broad-spectrum anti-inflammatory rather than narrowly anti-allergic.

The mechanistic findings supported the picture that fisetin acts upstream of the NF-κB signalsome — affecting IKK (I-κB kinase) activation or upstream signaling kinases — rather than competing with NF-κB at the DNA-binding level. This places fisetin in the same class as several pharmaceutical anti-inflammatory drugs that target the IKK / NF-κB axis.

The Hendriks work also helped establish that fisetin's effects on neuroinflammation (microglial activation, discussed on the Brain Health page) and on senescence-associated SASP cytokine production (discussed on the Senolytic page) are mechanistically continuous with its better-established anti-inflammatory effects in classical immune cells. The cell-type details vary; the NF-κB suppression is shared.

Back to Table of Contents

NF-κB Inhibition Mechanism

Nuclear factor kappa B (NF-κB) is the master transcription factor controlling expression of hundreds of pro-inflammatory genes. NF-κB is held in the cytoplasm in inactive form bound to its inhibitor I-κB. Upon activation (by TLR ligands, cytokine receptors, antigen receptors, oxidative stress, and many other triggers), I-κB is phosphorylated by IKK, ubiquitinated, and degraded by the proteasome. Free NF-κB translocates to the nucleus and drives transcription of:

NF-κB activation is appropriate for acute infection clearance. Chronic NF-κB activation underlies essentially every chronic inflammatory disease: rheumatoid arthritis, inflammatory bowel disease, atherosclerosis, type-2 diabetes, neurodegenerative diseases, and cancer.

Fisetin inhibits NF-κB activation at multiple points:

The multi-point inhibition makes the net effect robust — even if one intervention point is partial, the cumulative effect on downstream gene expression is substantial. This is the mechanistic basis for fisetin's broad anti-inflammatory profile across disparate cell types and disease models.

Back to Table of Contents

Mast Cell Stabilization in Detail

Mast cells are tissue-resident immune cells with primary granules containing histamine, heparin, tryptase, and chymase, and secondary mediators including leukotrienes, prostaglandins, and cytokines. They are positioned at the body's interfaces with the outside world (skin, gut, airway, conjunctiva) where they participate in defense against parasites and venoms and in classical IgE-mediated allergic reactions.

Mast-cell stabilizers prevent or attenuate degranulation in response to IgE-cross-linking or other triggers. The pharmaceutical mast-cell stabilizers (cromolyn sodium, nedocromil, ketotifen) are used clinically for asthma, allergic rhinitis, and ocular allergy. Several natural flavonoids including quercetin and fisetin also have mast-cell-stabilizing activity through partially overlapping but not identical mechanisms.

Fisetin's mast-cell-stabilizing mechanism includes:

The clinical relevance is for patients with mast-cell activation syndrome (MCAS), chronic urticaria, allergic rhinitis, atopic dermatitis with mast-cell-mediated flares, and food allergy. Quercetin has the larger published clinical evidence base for these applications; fisetin is mechanistically interchangeable and can be substituted or combined.

For more on mast cell activation, see our Mast Cell Activation Syndrome page.

Back to Table of Contents

Allergic Asthma and Airway Inflammation

Animal models of allergic asthma typically use ovalbumin sensitization and challenge in BALB/c mice to produce a Th2-skewed airway inflammation with eosinophil recruitment, mucus hypersecretion, and airway hyperresponsiveness. Fisetin treatment in these models reduces:

The mechanism in this context combines mast-cell stabilization, NF-κB inhibition in airway epithelium and immune cells, and direct effects on Th2 cytokine production. The animal data justifies clinical translation; human asthma trials of fisetin specifically have not been published, though quercetin trials in asthma and allergic rhinitis have shown modest benefit.

For more on asthma and respiratory inflammation, see our Asthma page and Pulmonology landing page.

Back to Table of Contents

Atopic Dermatitis and Skin Allergy

Atopic dermatitis (eczema) is a chronic inflammatory skin disease with both barrier-function and immune-dysregulation components. Mast-cell activation and Th2-skewed inflammation contribute to flares. Topical and oral flavonoids including fisetin have been tested as adjuncts to standard topical-corticosteroid management.

The pilot data for fisetin in atopic dermatitis is limited:

Clinically, the pragmatic use of fisetin (or quercetin) in atopic dermatitis is as an adjunct to standard care — topical corticosteroids or calcineurin inhibitors during flares, with supplemental flavonoid taken orally for ongoing background anti-inflammatory effect. The evidence is insufficient to recommend fisetin as monotherapy.

For more on dermatologic inflammation, see our Dermatology landing page.

Back to Table of Contents

Inflammatory Bowel Disease Models

Animal models of inflammatory bowel disease (dextran sulfate sodium colitis in mice, TNBS colitis, IL-10 knockout spontaneous colitis) all show benefit from fisetin treatment. Specific findings:

The mechanism combines the broad NF-κB inhibition, the senolytic clearance of senescent cells in inflamed gut tissue, and direct support of epithelial barrier function. The clinical translation to human IBD is plausible but has not been formally tested in large trials. Smaller pilot studies of quercetin in ulcerative colitis show modest benefit.

For more on IBD, see our Inflammatory Bowel Disease page, Crohn's Disease page, and Ulcerative Colitis page.

Back to Table of Contents

Rheumatoid and Osteoarthritis Applications

Fisetin has been tested in animal models of both rheumatoid arthritis (collagen-induced arthritis, CIA) and osteoarthritis (monosodium-iodoacetate-induced cartilage degradation). The findings:

The osteoarthritis application is mechanistically particularly interesting because senescent chondrocytes are increasingly recognized as drivers of OA progression. The senolytic mechanism that drives fisetin's lifespan effects may also clear senescent chondrocytes from OA cartilage, slowing disease progression. Several human OA trials of fisetin are now in progress (listed at ClinicalTrials.gov), making this one of the most-actively-investigated specific indications.

For more on arthritis, see our Arthritis page, Rheumatoid Arthritis page, and Osteoarthritis page.

Back to Table of Contents

COX-2 and Pro-Inflammatory Cytokine Suppression

Cyclooxygenase-2 (COX-2) is the inducible isoform of cyclooxygenase — the enzyme that converts arachidonic acid to prostaglandins. COX-2 is upregulated in inflammation and is the target of the NSAID class of drugs (ibuprofen, naproxen, celecoxib, etc.). Selective COX-2 inhibition produces analgesia and anti-inflammatory effects but carries cardiovascular and gastrointestinal risks.

Fisetin inhibits COX-2 expression at the transcriptional level (downstream of NF-κB inhibition) and may also directly inhibit COX-2 enzymatic activity at higher concentrations. The clinical relevance is for conditions where NSAID use is desired but where chronic NSAID exposure is problematic — older adults with renal insufficiency, patients with peptic ulcer history, patients on anticoagulants where bleeding risk is elevated.

Fisetin should not be considered a replacement for NSAIDs in acute pain management — the onset is slower and the analgesic potency is much lower. It can plausibly be used as part of a multi-component anti-inflammatory regimen to reduce the NSAID burden in chronic inflammatory conditions.

The cytokine suppression effect on IL-6, TNF-α, IL-1β, and IL-8 is documented in multiple cell types and tissue models. These are the same cytokines that drive systemic inflammaging in older adults, and they are the cytokines elevated in metabolic syndrome, obesity, and chronic-disease states. Fisetin's suppression of these cytokines is one mechanism by which it may produce broad health effects independent of the senolytic application.

Back to Table of Contents

Practical Anti-Inflammatory Use Cases

For patients considering fisetin specifically for its anti-inflammatory or anti-allergic applications (rather than for the senolytic application), the practical considerations:

For the integrated picture across all four fisetin benefit categories, see the Fisetin Benefits Hub.

Back to Table of Contents

Key Research Papers

  1. Park HH, Lee S, Son HY, et al. (2007). Flavonoids inhibit histamine release and expression of proinflammatory cytokines in mast cells. Archives of Pharmacal Research 30:1303-1311. — PubMed
  2. Hendriks JJA, et al. (2008). Fisetin inhibits proinflammatory cytokine and NF-κB signaling in immune cells. — PubMed
  3. Khan N, Syed DN, Ahmad N, Mukhtar H (2013). Fisetin: a dietary antioxidant for health promotion. Antioxidants & Redox Signaling 19:151-162. — PubMed
  4. Pal HC, Pearlman RL, Afaq F (2016). Fisetin and its role in chronic diseases. Advances in Experimental Medicine and Biology 928:213-244. — PubMed
  5. Geraets L, Moonen HJ, Brauers K, Wouters EF, Bast A, Hageman GJ (2007). Dietary flavones and flavonoles are inhibitors of poly(ADP-ribose) polymerase-1 in pulmonary epithelial cells. Journal of Nutrition 137:2190-2195. — PubMed
  6. Wu MY, Hung SK, Fu SL (2011). Immunosuppressive effects of fisetin in ovalbumin-induced asthma through inhibition of NF-κB activity. Journal of Agricultural and Food Chemistry 59:10496-10504. — PubMed
  7. Sahu BD, Kalvala AK, Koneru M, et al. (2014). Ameliorative effect of fisetin on cisplatin-induced nephrotoxicity in rats via modulation of NF-κB activation and antioxidant defence. PLOS ONE 9:e105070. — PubMed
  8. Kim JE, Son JE, Jung SK, et al. (2011). Fisetin, a dietary flavonoid, induces apoptosis of cancer cells by inhibiting HUWE1, a ubiquitin ligase. Cancer Research 71:8009-8019. — PubMed
  9. Zheng W, Feng Z, You S, et al. (2017). Fisetin inhibits IL-1β-induced inflammatory response in human osteoarthritis chondrocytes through activating SIRT1 and attenuates the progression of osteoarthritis in mice. International Immunopharmacology 45:135-147. — PubMed
  10. Sung B, Pandey MK, Aggarwal BB (2007). Fisetin, an inhibitor of cyclin-dependent kinase 6, down-regulates nuclear factor-κB-regulated cell proliferation, antiapoptotic and metastatic gene products. Molecular Pharmacology 71:1703-1714. — PubMed
  11. Lee KM, Lee KW, Jung SK, et al. (2010). Kaempferol inhibits UVB-induced COX-2 expression by suppressing Src kinase activity. Biochemical Pharmacology 80:2042-2049. — PubMed
  12. Quercetin and mast cell stabilization in clinical use review — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents